FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2938381018> ?p ?o ?g. }

• W2938381018 endingPage "3078" @default.
• W2938381018 startingPage "3061" @default.
• W2938381018 abstract "Efficacy and safety of olaparib maintenance therapy in platinum-sensitive ovarian cancer patients with BRCA mutations: a meta-analysis on randomized controlled trials Jiao Ma,1 Hongyong Deng,2 Jiajia Li,1 Shaopu Hu,3 Yanping Yang,3 Sheng Liu,1 Xianghui Han11Institute of Chinese Traditional Surgery, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200032, People’s Republic of China; 2Key Laboratory of Theory and Therapy of Muscles and Bones, Ministry of Education, Shanghai 200032, People’s Republic of China; 3Science and Information Center, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, People’s Republic of ChinaBackground: Olaparib, a potent oral poly (ADP-ribose) polymerase inhibitor, exhibits antitumor activity and prevents the recurrence in advanced ovarian cancer. In this article, we assessed the efficacy and safety of olaparib maintenance therapy on platinum-sensitive ovarian cancer patients with BRCA mutations through a meta-analysis of available randomized controlled trials (RCTs) to provide more evidence for its clinical applications.Methods: We searched PubMed, Embase, Wanfang, CNKI, Web of Science, Cochrane Library, and VIP databases from 1 August 2018 to identify RCTs and finally included four RCTs (seven articles) with 567 eligible participants beyond the participants, interventions, comparisons, outcomes, and study design regulation. The outcomes of olaparib efficacy including progression-free survival (PFS) and overall survival (OS) were measured by HR and 95% CI, while the quality of life was evaluated by calculating the combination of P-value. Seven common adverse events were tested by risk ratio and 95% CI as the outcomes of olaparib safety. These data were analyzed, and the forest figures were produced using Review Manager 5.3.Results: Compared with other interventions (ie, placebo or chemotherapy drugs), olaparib significantly prolonged PFS (HR=0.31, 95% CI=0.15–0.62) and slightly improved OS (HR=0.75, 95% CI=0.56–0.99), but did not influence the quality of life (P=0.058) in the patients with platinum-sensitive BRCA-mutated ovarian cancer. Additionally, the toxicity profile of olaparib involved anemia, fatigue, vomiting, diarrhea, and nausea with grade 1–2.Conclusion: This meta-analysis suggests that olaparib maintenance therapy is effective and well-tolerated for the patients with platinum-sensitive BRCA-mutated ovarian cancer. More updated RCTs and long-term follow-up should be conducted to compare and analyze the efficacy and toxicity of olaparib at different doses in ovarian cancer patients.Keywords: olaparib, ovarian cancer, efficacy, adverse event, meta-analysis" @default.
• W2938381018 created "2019-04-25" @default.
• W2938381018 creator A5009869157 @default.
• W2938381018 creator A5013305484 @default.
• W2938381018 creator A5026029074 @default.
• W2938381018 creator A5032397876 @default.
• W2938381018 creator A5076621575 @default.
• W2938381018 creator A5085399047 @default.
• W2938381018 creator A5086823444 @default.
• W2938381018 date "2019-04-01" @default.
• W2938381018 modified "2023-09-26" @default.
• W2938381018 title "<p>Efficacy and safety of olaparib maintenance therapy in platinum-sensitive ovarian cancer patients with <em>BRCA</em> mutations: a meta-analysis on randomized controlled trials</p>" @default.
• W2938381018 cites W2014035904 @default.
• W2938381018 cites W2014599726 @default.
• W2938381018 cites W2025322581 @default.
• W2938381018 cites W2033816200 @default.
• W2938381018 cites W2065510755 @default.
• W2938381018 cites W2098123839 @default.
• W2938381018 cites W2110017381 @default.
• W2938381018 cites W2130078242 @default.
• W2938381018 cites W2147071985 @default.
• W2938381018 cites W2151509048 @default.
• W2938381018 cites W2160466424 @default.
• W2938381018 cites W2167237804 @default.
• W2938381018 cites W2168169655 @default.
• W2938381018 cites W2169862738 @default.
• W2938381018 cites W2171658624 @default.
• W2938381018 cites W2171972386 @default.
• W2938381018 cites W2235405584 @default.
• W2938381018 cites W2272984102 @default.
• W2938381018 cites W2294633761 @default.
• W2938381018 cites W2515679040 @default.
• W2938381018 cites W2519148856 @default.
• W2938381018 cites W2529607059 @default.
• W2938381018 cites W2550229146 @default.
• W2938381018 cites W2602633586 @default.
• W2938381018 cites W2606436364 @default.
• W2938381018 cites W2621271973 @default.
• W2938381018 cites W2737389832 @default.
• W2938381018 cites W2784806167 @default.
• W2938381018 cites W2883673963 @default.
• W2938381018 cites W3093265161 @default.
• W2938381018 doi "https://doi.org/10.2147/cmar.s191107" @default.
• W2938381018 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6489675" @default.
• W2938381018 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31114351" @default.
• W2938381018 hasPublicationYear "2019" @default.
• W2938381018 type Work @default.
• W2938381018 sameAs 2938381018 @default.
• W2938381018 citedByCount "9" @default.
• W2938381018 countsByYear W29383810182020 @default.
• W2938381018 countsByYear W29383810182021 @default.
• W2938381018 countsByYear W29383810182022 @default.
• W2938381018 countsByYear W29383810182023 @default.
• W2938381018 crossrefType "journal-article" @default.
• W2938381018 hasAuthorship W2938381018A5009869157 @default.
• W2938381018 hasAuthorship W2938381018A5013305484 @default.
• W2938381018 hasAuthorship W2938381018A5026029074 @default.
• W2938381018 hasAuthorship W2938381018A5032397876 @default.
• W2938381018 hasAuthorship W2938381018A5076621575 @default.
• W2938381018 hasAuthorship W2938381018A5085399047 @default.
• W2938381018 hasAuthorship W2938381018A5086823444 @default.
• W2938381018 hasBestOaLocation W29383810181 @default.
• W2938381018 hasConcept C104317684 @default.
• W2938381018 hasConcept C121608353 @default.
• W2938381018 hasConcept C126322002 @default.
• W2938381018 hasConcept C143998085 @default.
• W2938381018 hasConcept C168563851 @default.
• W2938381018 hasConcept C182979987 @default.
• W2938381018 hasConcept C187960798 @default.
• W2938381018 hasConcept C197934379 @default.
• W2938381018 hasConcept C2776478404 @default.
• W2938381018 hasConcept C2779962180 @default.
• W2938381018 hasConcept C2780194787 @default.
• W2938381018 hasConcept C2780427987 @default.
• W2938381018 hasConcept C29456083 @default.
• W2938381018 hasConcept C55493867 @default.
• W2938381018 hasConcept C71924100 @default.
• W2938381018 hasConcept C82381507 @default.
• W2938381018 hasConcept C86803240 @default.
• W2938381018 hasConcept C95190672 @default.
• W2938381018 hasConceptScore W2938381018C104317684 @default.
• W2938381018 hasConceptScore W2938381018C121608353 @default.
• W2938381018 hasConceptScore W2938381018C126322002 @default.
• W2938381018 hasConceptScore W2938381018C143998085 @default.
• W2938381018 hasConceptScore W2938381018C168563851 @default.
• W2938381018 hasConceptScore W2938381018C182979987 @default.
• W2938381018 hasConceptScore W2938381018C187960798 @default.
• W2938381018 hasConceptScore W2938381018C197934379 @default.
• W2938381018 hasConceptScore W2938381018C2776478404 @default.
• W2938381018 hasConceptScore W2938381018C2779962180 @default.
• W2938381018 hasConceptScore W2938381018C2780194787 @default.
• W2938381018 hasConceptScore W2938381018C2780427987 @default.
• W2938381018 hasConceptScore W2938381018C29456083 @default.
• W2938381018 hasConceptScore W2938381018C55493867 @default.
• W2938381018 hasConceptScore W2938381018C71924100 @default.
• W2938381018 hasConceptScore W2938381018C82381507 @default.
• W2938381018 hasConceptScore W2938381018C86803240 @default.
• W2938381018 hasConceptScore W2938381018C95190672 @default.

• next